AbbVie has agreed to buy Capstan Therapeutics for up to $2.1 billion, expanding its pipeline with a potential first-in-class ...

The biotech, which agreed to be bought by Supernus after clinical and commercial struggles, plans to lay off 338 employees by ...

Notice of the Cambridge biotech's layoffs came less than two weeks after Sage announced it would be acquired by ...

Two weeks after Supernus Pharmaceuticals unveiled the proposed acquisition of Sage Therapeutics, all 338 employees from the latter company are being canned, ...

Sage had 338 full-time employees, all of whom will be laid off effective Aug. 22. The layoffs were announced a few weeks ...

In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Hold rating on Biogen (BIIB – Research Report), with a price target of $140.00. The company’s shares ...

Analysts have also noted that the relatively low breakup fee may leave room for a competing offer, possibly from Biogen.

JPMorgan cut its price target on Sage Therapeutics to $8.5 from $11 based on the recently announced buyout by Supernus ...

LONDON, GREATER LONDON, UNITED KINGDOM, June 20, 2025 /EINPresswire.com/ -- Prominently, the neuroplasticity market size has seen significant exponential growth in recent years. In particular, the ...

Detailed price information for Sage Therapeutic Com (SAGE-Q) from The Globe and Mail including charting and trades.

Supernus Pharmaceuticals (Nasdaq: SUPN) is to buy Sage Therapeutics (Nasdaq: SAGE) for total consideration of around $795 ...

In what one analyst described as an “unremarkable” outcome, the brain drug developer is being acquired for just $8.50 per ...